Search

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Telemedicine – the standalone study that became the new normal

Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!

Occupational Health and Safety

Grass Roots Innovation Overview

Video providing an overview of the Grass Roots Innovation Program and how the activities support the next generation of life-science innovators and entrepreneurs

Ridgefield, CT | BI Facilities

BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

Cookie Statement

Boehringer Ingelheim Cares Product Donations Program

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

Boehringer Ingelheim Innovation Prize Video 2023

Video providing an overview of the Innovation Prize initiative and the benefits of participating and receiving the award.

Corporate Compliance Program

What can the Patient do?

What you need to know about counterfeit medicines

Understand the risk of counterfeit medication.

Partnering Culture

BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.

1885-1948: Innovative Beginnings | Boehringer Ingelheim US

Click here to read an in-depth history of Boehringer Ingelheim's formation, early days and what led us to being the global pharmaceutical company of today.

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

Innovation in CNS Disease Research

Data Career

Data science at Boehringer Ingelheim is more than just solving fascinating problems. A chance to provide innovative solutions that bring value and hope to people.

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.

USDA & BI Expand Research Opportunities | Boehringer Ingelheim US

Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.

US Privacy Statement

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers